FDA Accepts Gilead's NDA for Idelalisib Against Indolent Lymphomas

According to Gilead Sciences, a biopharmaceutical company in the business of innovative therapeutics based in the San Francisco Bay area, the US Food and Drug Administration has accepted for review the company's New Drug Application (NDA) for idelalisib.

Idelalisib is an investigational, highly selective oral inhibitor of phosphoinositide 3-kinase (PI3K) delta. PI3K delta signaling is critical for the activation, proliferation, survival and trafficking of B lymphocytes and is hyperactive in many B-cell malignancies.

The current NDA is for the treatment of refractory indolent non-Hodgkin's lymphoma (iNHL).

Gilead submitted the NDA on Sept. 11, 2013. Since the FDA granted standard review, it has set a target review date under the Prescription Drug User Fee Act (PDUFA) of Sept. 11, 2014.

Gilead's NDA for iNHL is supported by a single arm Phase II study evaluating idelalisib in patients with iNHL that is considered refractory to rituximab and to alkylating-agent-containing chemotherapy.

The FDA previously granted idelalisib a Breakthrough Therapy designation for relapsed chronic lymphocytic leukemia (CLL), and Gilead previously submitted an NDA for the same drug back in December of 2013 for CLL treatment.

Source: Gilead

More Articles

More Articles

In T cell lymphoma, T lymphocytes, which are an essential part of the body's immune response, become malignant. T cell lymphomas account for about...

Lymphomatoid Papulosis (LyP) is a rare skin disorder that involves cancerous looking skin lesions. It is more than a skin condition; it is the...

In non-Hodgkin's lymphoma, you have your B-cell lymphomas and you have your T-cell lymphomas.

Why B...

MALT lymphoma is a rare B-cell non-Hodgkin's lymphoma that typically runs an indolent or slow-growing clinical...

Mantle cell lymphoma (MCL) is a relatively rare B-cell subtype of non-Hodgkin'...

T-Cell Lymphoblastic Lymphoma (T-LBL) is a very rare subtype of non-Hodgkin's lymphoma. It tends to develop in...

In general, a diagnosis of T-cell lymphoma denotes a poorer prognosis than a diagnosis of B-cell lymphoma. One of...

Mantle cell lymphoma (MCL) is just one of 50-60 known B-cell subtypes of...

After some of the dust has settled, the thoughts of many new lymphoma patients turn to diet and nutrition. They want to know if, in the past,...

The term NK T cell lymphoma refers to one of two subtypes of lymphoma that affect the NK (Natural Killer)...

In a perfect world, every case of cancer would respond to, and be cured by first-line therapy. Unfortunately, it is not often the case. This is...

Prednisone is a glucocorticosteroid (a steroid) used in the treatment of many types of cancers. It functions as an anti-inflammatory medicine that...

In 1964, researchers at the National Cancer Institute developed the first combination chemotherapy that cured a...